MedPath

UNIVERSITY OF CINCINNATI

🇺🇸United States
Ownership
-
Established
1819-01-01
Employees
5.9K
Market Cap
-
Website
https://www.uc.edu/

Clinical Trials

307

Active:23
Completed:173

Trial Phases

6 Phases

Early Phase 1:4
Phase 1:23
Phase 2:41
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (252 trials with phase data)• Click on a phase to view related trials

Not Applicable
103 (40.9%)
Phase 4
60 (23.8%)
Phase 2
41 (16.3%)
Phase 1
23 (9.1%)
Phase 3
21 (8.3%)
Early Phase 1
4 (1.6%)

Gender-affirming Voice Training With Visual Feedback

Not Applicable
Not yet recruiting
Conditions
Transgender Women
Voice Alteration
First Posted Date
2025-06-12
Last Posted Date
2025-06-12
Lead Sponsor
University of Cincinnati
Target Recruit Count
5
Registration Number
NCT07017595

Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia

Not Applicable
Recruiting
Conditions
Eldery People
Cognitive Decline
Memory Decline
DHA CNS Delivery
First Posted Date
2025-04-18
Last Posted Date
2025-06-15
Lead Sponsor
University of Cincinnati
Target Recruit Count
153
Registration Number
NCT06933095
Locations
🇺🇸

University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati, Ohio, United States

Promoting Adherence to Chemotherapy Handling Guidelines Among Oncology Nurses

Not Applicable
Not yet recruiting
Conditions
Chemotherapy Exposure
Handling Guidelines
Oncology Nurse
Adherence
First Posted Date
2025-04-09
Last Posted Date
2025-05-06
Lead Sponsor
University of Cincinnati
Target Recruit Count
60
Registration Number
NCT06919653
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Early Neuromodulation in Traumatic Brain Injury

Not Applicable
Recruiting
Conditions
Traumatic Brain Injury (TBI) Patients
First Posted Date
2025-03-11
Last Posted Date
2025-05-29
Lead Sponsor
University of Cincinnati
Target Recruit Count
60
Registration Number
NCT06871124
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains

Not Applicable
Recruiting
Conditions
Depression - Major Depressive Disorder
First Posted Date
2025-01-28
Last Posted Date
2025-05-06
Lead Sponsor
University of Cincinnati
Target Recruit Count
67
Registration Number
NCT06795451
Locations
🇺🇸

Lindner Center of Hope, Mason, Ohio, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 62
  • Next

News

AM-101 Enhances Radiation Therapy Efficacy in Lung Cancer with Brain Metastasis

Researchers have discovered that AM-101, a synthetic benzodiazepine analog, can enhance the efficacy of radiation therapy for lung cancer that has metastasized to the brain.

Progesterone Drug Provera Linked to Vision Loss in Meningioma Patients

A recent study identifies progesterone, specifically Provera, as a significant risk factor for vision loss related to meningiomas in premenopausal women.

Alzheimer's Drugs May Work by Boosting Healthy Amyloid Beta Protein, Study Suggests

• New research suggests Alzheimer's drugs like lecanemab and donanemab may slow disease progression by increasing levels of healthy amyloid beta (Aβ42) protein in the brain. • The study challenges the prevailing theory that these drugs work solely by reducing toxic amyloid plaques, highlighting the potential importance of soluble Aβ42 in maintaining brain health. • Researchers analyzed data from nearly 26,000 patients, finding that increased levels of soluble Aβ42 correlated with slower Alzheimer's progression during treatment with these monoclonal antibodies. • The study authors propose alternative therapies focused on boosting soluble Aβ42 levels directly, rather than solely targeting amyloid plaques, which may have long-term risks.

© Copyright 2025. All Rights Reserved by MedPath